Loading...
Docoh

Acura Pharmaceuticals (ACUR)

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

ACUR stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 May 22
12 Aug 22
31 Dec 22
Quarter (USD) Sep 21 Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 89K 89K 89K 89K 89K 89K
Cash burn (monthly) 26K 33.67K 177K 118.33K (no burn) 33K
Cash used (since last report) 271.65K 351.75K 1.85M 1.24M n/a 344.78K
Cash remaining -182.65K -262.75K -1.76M -1.15M n/a -255.78K
Runway (months of cash) -7.0 -7.8 -9.9 -9.7 n/a -7.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Aug 22 Peter A Clemens Common Stock Option exercise Acquire M No No 0 49,333 0 465,430
3 Aug 22 Peter A Clemens RSU Common Stock Option exercise Acquire M No No 0.01 40,000 400 80,000
3 Aug 22 Peter A Clemens RSU Common Stock Option exercise Acquire M No No 0.01 9,333 93.33 120,000
3 Aug 22 Robert B Jones Common Stock Option exercise Acquire M No No 0 63,666 0 553,555
3 Aug 22 Robert B Jones RSU Common Stock Option exercise Acquire M No No 0.01 50,000 500 90,000
3 Aug 22 Robert B Jones RSU Common Stock Option exercise Acquire M No No 0.01 13,666 136.66 140,000
3 Aug 22 Robert A Seiser Common Stock Option exercise Acquire M No No 0 24,666 0 378,254
3 Aug 22 Robert A Seiser RSU Common Stock Option exercise Acquire M No No 0.01 20,000 200 60,000
3 Aug 22 Robert A Seiser RSU Common Stock Option exercise Acquire M No No 0.01 4,666 46.66 80,000
3 Aug 22 Albert W Brzeczko Common Stock Option exercise Acquire M No No 0 43,333 0 412,001
81.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2 2
Opened positions 0 0
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 21.49M 21.49M
Total shares 52.99M 52.99M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Schutte John 52.98M $21.49M 0.0%
Lenox Wealth Advisors 780 $0 0.0%
Largest transactions Shares Bought/sold Change
Lenox Wealth Advisors 780 0 0.0%
Schutte John 52.98M 0 0.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Letter, physiologic, Sep, stringent
Removed: accruing, beginning, commitment, disbursement, epidemiology, granting

Patents

Utility
Methods and Compositions for Interfering with Extraction or Conversion of a Drug Susceptible to Abuse
3 Mar 22
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
Utility
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
14 Dec 21
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
Utility
Methods and Compositions for Self-regulated Release of Active Pharmaceutical Ingredient
28 Oct 21
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
31 Aug 21
An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
10 Aug 21
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.